Who are Ketoconazole tablet's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Loceryl NL 12 weeks, Topical Clotrimazole cream, Terconazole Vaginal Suppository, Topical ketoconazole 2% cream, Topical Sertaconazole 2%, Canesten®.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ketoconazole-tablet.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Ketoconazole tablet — Competitive Intelligence Brief

Ketoconazole tablet (Ketoconazole tablet) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Azole antifungal. Area: Infectious Disease.

phase 2 Azole antifungal Lanosterol 14α-demethylase Infectious Disease Small molecule Live · refreshed every 30 min

Target snapshot

Ketoconazole tablet (Ketoconazole tablet) — Purdue Pharma LP. Ketoconazole is a broad-spectrum antifungal agent that inhibits the synthesis of ergosterol, a vital component of fungal cell membranes, by blocking the cytochrome P450-dependent enzyme lanosterol 14α-demethylase.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Ketoconazole tablet TARGET	Ketoconazole tablet	Purdue Pharma LP	phase 2	Azole antifungal	Lanosterol 14α-demethylase
Loceryl NL 12 weeks	Loceryl NL 12 weeks	Galderma R&D	marketed	Allylamine antifungal	Lanosterol 14α-demethylase (CYP51)
Topical Clotrimazole cream	Topical Clotrimazole cream	Hayat Abad Medical Complex, Peshawar	marketed	Imidazole antifungal	Fungal lanosterol 14α-demethylase (CYP51)
Terconazole Vaginal Suppository	Terconazole Vaginal Suppository	Hatem AbuHashim	marketed	Azole antifungal	Lanosterol 14α-demethylase (CYP51)
Topical ketoconazole 2% cream	Topical ketoconazole 2% cream	PAEC General Hospital, Islamabad	marketed	Imidazole antifungal	Fungal cytochrome P450 (CYP51 / lanosterol 14α-demethylase)
Topical Sertaconazole 2%	Topical Sertaconazole 2%	Jinnah Postgraduate Medical Centre	marketed	Imidazole antifungal	Lanosterol 14α-demethylase (CYP51)
Canesten®	Canesten®	Ache Laboratorios Farmaceuticos S.A.	marketed	Imidazole antifungal	Lanosterol 14α-demethylase (CYP51)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Azole antifungal class)

Pfizer · 3 drugs in this class
Elion Therapeutics, Inc. · 1 drug in this class
Hadassah Medical Organization · 1 drug in this class
Hatem AbuHashim · 1 drug in this class
Janssen Pharmaceutical K.K. · 1 drug in this class
Jiangsu Aosaikang Pharmaceutical Co., Ltd. · 1 drug in this class
Military Hospital of Tunis · 1 drug in this class
Mycovia Pharmaceuticals Inc. · 1 drug in this class
Nuvation Bio Inc. · 1 drug in this class
Purdue Pharma LP · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Ketoconazole tablet — Competitive Intelligence Brief. https://druglandscape.com/ci/ketoconazole-tablet. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab